RB homepage

lung cancer pulmonary nodule

More accurate response assessments could give providers an opportunity to proactively manage treatment decisions in the future.

candles-209157_960_720.jpg

His former colleagues say he was a "ceaseless champion for advancing the radiology industry" and that his contributions to the field "will be remembered with immense gratitude.” 

Dr. Nee Khoo, director of the echocardiography lab, Stollery Children’s Hospital, Edmonton, Canada, explains the rapidly growing adoption of pediatric 3D transesophageal echo (TEE) to not only preplan, but also guide and assess the results of congenital heart surgeries.

Nee Khoo, MBChB, director of the echocardiography lab at Canada's Stollery Children’s Hospital, explains the rapid adoption of pediatric 3D transesophageal echo.

Medical Bills

The exam effectively helps providers manage patients’ treatment options, but for some, the costs associated with those treatments may negate the value of its findings.

potential new tariffs on medical devices, imaging equipment, PPE and more

RSNA, RadNet, the RBMA and Japanese imaging leaders all recently spoke out against the possibility of more fees on device imports. 

Neiman researchers recently scoured for factors that might impact screening rates across cancers of the colon/rectum, lung, breast and prostate, using nationwide Medicare data.

Innovation at work

Six years ago, two radiologists with dissimilar backgrounds and divergent clinical interests put their heads together and launched a new practice. One physician was an academic subspecialized in musculoskeletal reads. The other, a private practitioner, concentrated on oncologic imaging. That’s how Transparent Imaging was born, powered by Konica Minolta. 

Sponsored by Konica Minolta

In a private dining room in Miami, something unusual is happening. Leaders from competing imaging centers are openly discussing their best practices—even sharing vendor recommendations and operational strategies that have doubled their volumes while cutting costs in half.

In cooperation with AbbaDox

Around the web

A growing number of private insurers are now covering these advanced technologies. Roosha Parikh, MD, told Cardiovascular Business that the hard work of SCCT and other groups has helped make this happen. 

Customers are urged to stop using these devices right away.

Researchers used AI-enabled software developed by Cleerly to evaluate the CCTA results of more than 6,000 patients. The software was consistently effective, identifying patients who may face an increased risk of poor outcomes.